IFP Advisors’s VanEck Vectors Generic Drugs ETF GNRX Stock Holding History

IFP Advisors’s Portfolio GNRX Stock Details GNRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-2,250	Closed	-$51K	–	4391
2017 Q1	$51K	Hold	2,250	–	–	﹤0.01%	1920
2016 Q4	$48K	Hold	2,250	–	–	﹤0.01%	1914
2016 Q3	$55K	Hold	2,250	–	–	﹤0.01%	1760
2016 Q2	$54K	Buy	+2,250	New	+$53.7K	﹤0.01%	1725

Other funds holding GNRX

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

IFP Advisors's GNRX Position: Q2 2017 in Review

IFP Advisors sold out of VanEck Vectors Generic Drugs ETF (GNRX) in Q2 2017, closing a stake of 2,250 shares — an estimated $51K sold.

IFP Advisors first reported a position in GNRX in Q2 2016 and held it in 4 quarters. The position peaked at $55K in Q3 2016. 3 funds tracked by Wall St. Rank hold GNRX as of Q2 2017.

IFP Advisors reported no remaining VanEck Vectors Generic Drugs ETF position as of Q2 2017 after selling out during the quarter.
IFP Advisors sold 2,250 VanEck Vectors Generic Drugs ETF shares in Q2 2017, an estimated $51K.
IFP Advisors first reported a position in VanEck Vectors Generic Drugs ETF in Q2 2016 and held it in 4 quarters.
IFP Advisors's VanEck Vectors Generic Drugs ETF position peaked at $55K in Q3 2016.
3 funds tracked by Wall St. Rank held VanEck Vectors Generic Drugs ETF as of Q2 2017.

Based on IFP Advisors's 13F filing for Q2 2017, filed 31 Jul 2017.